JiHun Jang

Mr. JiHun Jang


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2020 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
DKDong Jun Kim
Dong Jun Kim
JJJiHun Jang
JiHun Jang
SHSoo-Youn Ham
Soo-Youn Ham
SCSeong Hee Choi
Seong Hee Choi
SPSung Soon Park
Sung Soon Park
WCWha Ja Cho
Wha Ja Cho

1 January 2020 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
JJJiHun Jang
JiHun Jang
DKDong Jun Kim
Dong Jun Kim
SHSoo-Youn Ham
Soo-Youn Ham
MVMai-Tram Vo
Mai-Tram Vo
SJSo Yeon Jeong
So Yeon Jeong
JPJeong Woo Park
Jeong Woo Park

Verified
Journal Article
Open access
PDF file
HCHan-Byeol Choi
Han-Byeol Choi
RKRyeo Won Kim
Ryeo Won Kim
Gi-Sang BaeGi-Sang Bae
Gi-Sang Bae
JJJiHun Jang
JiHun Jang
YKYe-Seul Kim
Ye-Seul Kim
KKKang-Beom Kwon
Kang-Beom Kwon
The pathogenesis of inflammatory bowel diseases (IBD), such as ulcerative colitis and Crohn’s disease, remains incompletely understood. Amomum villosum Lour. (Zingiberaceae) is a traditional herbal medicine used across Asia to treat digestive and inflammatory disorders. This study investigated the therapeutic effects of a water extract derived from the fruits of AV (referred to as AVE) in a mouse model of colitis induced by dextran sulfate sodium (DSS). The protective effects of AVE were evaluated by monitoring changes in body weight and colon length, as well as histological and molecular markers of inflammation. Neutrophil infiltration and levels of inflammatory cytokines in colon tissue and serum were assessed, and the integrity of the intestinal epithelial barrier was examined via Western blot analysis. Treatment with AVE significantly alleviated DSS-induced colitis, as evidenced by improved body weight, longer colon length, and reduced inflammatory responses. AVE administration restored tight junction protein expression (zonula occludens-1 [ZO-1] and occludin), suppressed phosphorylation of mitogen-activated protein kinases—specifically, extracellular signal-regulated kinase (ERK) and p38—and inhibited the expression of inflammatory mediators including tumor necrosis factor-alpha (TNF-α), cyclooxygenase-2 (COX-2), interleukin (IL)-6, IL-1β, and myeloperoxidase (MPO) activity. These findings suggest that oral AVE treatment effectively protects against experimental colitis by modulating inflammatory signaling and preserving epithelial barrier integrity. Further studies are warranted to explore the clinical potential and safety of AVE in the management of IBD.